Pharmaceutical company Moderna says it is scaling down its investments in late-stage vaccine trials amid growing opposition ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

Check out the companies making headlines in midday trading. Fortinet — Shares jumped more than 7% after TD Cowen upgraded the cybersecurity stock to buy from hold, saying rising memory prices won't ...

The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower ...

The Cleburne Railroaders officially unveiled their refreshed logo and brand identity Thursday at La Moderna Field, marking ...

News, features, and commentary about cancer-related issues ...

The label on the pill bottles found in warehouses in nine states said Biktarvy or Descovy, both antiviral HIV medications ...

Qiagen was the second-best performer, with a weekly return of 16.92%. The 3-star stock has gained 10.76% over the last three ...

In the splendid setting of the Foreign Press Association in Italy, at Palazzo Grazioli, the ceremony of the I Premio Stampa d ...

BY VICTOR SALEH The promise of artificial intelligence (AI) is everywhere, but the reality for many businesses ...

GSK is set to buy Rapt Therapeutics in a $2.2 billion deal. AstraZeneca agreed to a $630 million pact to secure remaining rights to armored CAR-T from AbelZeta. Bristol Myers Squibb signed a deal with ...